newsfilter
← Latest News
GlobeNewswire·

Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC

  • Black Diamond Therapeutics will host an investor webcast on Tuesday, November 10, 2026, at 7:30 a.m. ET.
  • The event will present updated Phase 2 trial results for silevertinib in frontline patients with EGFR-mutated non-small cell lung cancer.
  • The company will share FDA feedback supporting a clear Phase 3 path to potential accelerated approval for silevertinib in that patient population.
  • Silevertinib is an investigational, brain-penetrant, fourth-generation tyrosine kinase inhibitor targeting classical & over 50 non-classical EGFR mutations in NSCLC.
  • Over 200 patients with EGFRm NSCLC or EGFR-altered glioblastoma multiforme have been treated with silevertinib to date.
  • A randomized Phase 2 trial for silevertinib in newly diagnosed EGFRvIII-positive GBM is also ongoing under identifier NCT07326566.
  • The webcast is accessible via the "Events and Presentations" section of the Black Diamond Therapeutics investor website, with a replay available for a limited time.
Company
Black Diamond Therapeutics, Inc
Keywords
Nasdaq:BDTX, Black Diamond Therapeutics, Inc